Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial compares the effect of sacituzumab govitecan and bevacizumab to standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with ovarian cancer that has come back after an initial response to platinum therapy (platinum-sensitive), that has progressed after poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor maintenance therapy (recurrent), and that has a mutation in the BRCA1 or BRCA2 genes or is homologous recombination deficient. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as TROP2 receptors, and delivers govitecan to kill them. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It also blocks a certain enzyme needed for cell division and DNA repair. Liposomal doxorubicin is a form of the anticancer drug doxorubicin that is contained inside very tiny, fat-like particles. Liposomal doxorubicin may have fewer side effects and work better than other forms of the drug. Giving sacituzumab govitecan and bevacizumab may kill more tumor cells than standard care (carboplatin, pegylated liposomal doxorubicin, and bevacizumab) in patients with recurrent platinum-sensitive ovarian cancers that have BRCA1/2 mutations or homologous recombination deficiency.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie wysoko złośliwy rak jajnika, jajnikowodu lub otrzewnej
- •Rak wrażliwy na platynę - progresja wystąpiła co najmniej 6 miesięcy po ostatniej dawce leku platynowego
- •Progresja nowotworu podczas pierwszej linii utrzymującego leczenia inhibitorem PARP
- •Mutacja BRCA1 lub BRCA2 albo pozytywny test na defekt rekombinacji homologicznej
- •Nowotwór mierzalny lub niemierzalny według kryteriów RECIST
- •Wiek co najmniej 18 lat
- •Dobry ogólny stan zdrowia (ECOG ≤ 2)
- •Prawidłowe wyniki badań krwi (liczba neutrofili, płytki, hemoglobina, funkcja nerek)
✗ Disqualifies
- •Poprzednie leczenie inhibitorami topoisomerazy I
- •Stosowanie innych badawczych leków w ciągu ostatnich 4 tygodni
- •Równoczesne stosowanie innej chemioterapii, terapii celowanej, immunoterapii lub hormonoterapii
- •Mniej niż 3 tygodnie od ostatniej dawki inhibitora PARP
- •Ciąża lub karmienie piersią
- •Niestabilne przerzuty do mózgu lub progresja choroby na ośrodkowym układzie nerwowym
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 5, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (9)
Highlands Oncology Group - Fayetteville
Fayetteville, United States
Highlands Oncology Group - Rogers
Rogers, United States
Highlands Oncology Group
Springdale, United States
Kootenai Health - Coeur d'Alene
Coeur d'Alene, United States
Kootenai Clinic Cancer Services - Post Falls
Post Falls, United States
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, United States
Mercy Hospital Springfield
Springfield, United States
Billings Clinic Cancer Center
Billings, United States
Community Medical Center
Missoula, United States
Trial contact
Site Public Contact
Ewa M. Matczak
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
John M. Schallenkamp
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jay W. Carlson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.